All In Biotech

NDA 050606 · Ani Pharms

Vancocin Hydrochloride

Vancomycin Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Dec 22, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Apr 15, 1986

Approved uses

3

Original approval plus efficacy supplements

Registered trials

501

123 Phase 3, 64 recruiting

FAERS reports

8,212

7,409 serious, 1,633 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 2, 2026.

Vancomycin Hydrochloride Capsules are indicated for the treatment of Clostridioides difficile -associated diarrhea. Vancomycin Hydrochloride Capsules are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in adult and pediatric patients less than 18 years of age. Limitations of Use • Parenteral administration of vancomycin is not effective for the above infections; therefore, Vancomycin Hydrochloride Capsules must be given orally for these infections. • Orally administered Vancomycin Hydrochloride Capsules are not effective for other types of infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride Capsules and other antibacterial drugs, Vancomycin Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Vancomycin Hydrochloride Capsules are a glycopeptide antibacterial indicated in adult and pediatric patients (less than 18 years of age) for the treatment of: ( 1 ) • Clostridioides difficile-associated diarrhea • Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) Limitations of Use: ( 1 ) ( 5.1 ) • Parenteral administration of vancomycin is not effective for the above infections; therefore, Vancomycin Hydrochloride Capsules must be given orally for these infections. • Orally administered Vancomycin Hydrochloride Capsules are not effective for other...

Mechanism: Vancomycin is an antibacterial drug [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 14, 2011 Supplement 28 · Efficacy LabelLetter
  • Mar 17, 2004 Original approval · Supplement
  • Apr 15, 1986 Original approval · Type 3 - New Dosage Form
2 products under this application
  • VANCOCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 250MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • VANCOCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 125MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective874
  • acute kidney injury582
  • off label use519
  • pyrexia482
  • rash345
  • drug reaction with eosinophilia and systemic symptoms317
  • pneumonia310
  • sepsis310
  • drug hypersensitivity305
  • diarrhoea296
  • condition aggravated283
  • hypotension258

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200551
200692
2007150
2008271
2009101
201092
2011108
2012167
2013236
2014217
2015320
2016230
2017244
2018361
2019468
2020524
2021682
2022964
2023959
2024818
2025699
2026396

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,708 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.